AM-Pharma is a biopharmaceutical company that focuses on the development of recombinant Alkaline Phosphatase for clinical use.

Iconic Therapeutics is a clinical-stage biopharmaceutical company dedicated to translating scientific knowledge into new medicines. The company's understanding of the role of the tissue factor in angiogenesis, inflammation, and malignancies has led it to a new approach to developing therapies for devastating diseases such as macular degeneration and cancer.

Aphios is a clinical stage biotechnology company. It develops technology platfroms to improve drug discovery and manufacturing, nanotechnology drug delivery and pathogenic safety. Based on these platforms, the company develops therapeutics to prevent disease, maintain health, and treat chronic diseases, including cancers and supportive care, infectious diseases such as HIV/AIDS, influenza and COVID-19. The company was founded in 2018 and is based in Woburn, Massachusetts.

Oligomerix is a clinical-stage biotechnology company. It focuses on developing disease-modifying therapeutics for neurodegenerative diseases characterized by the aberrant tau protein, ranging from tauopathies such as progressive supranuclear palsy and frontotemporal dementia to Alzheimer’s disease. The firm serves clients in the healthcare sector. Oligomerix was founded in 2006 and is based in West Harrison, New York.

ACUREON Pharmaceuticals is a United States biopharmaceutical company primarily focused on specialty therapeutics to improve patient outcomes in the hospital areas of Infectious Diseases, Transplant, and ICU. To address the needs of the market, Acureon Pharma is focused on exploring opportunities that selectively acquire and enhance the market potential of commercially available therapeutics and late-stage development drugs. The company is located in the western suburbs of Philadelphia.

Limerick BioPharma is developing compounds that per the company when used adjunctively with both marketed and investigational drugs improve drug side effect profiles and clinical outcomes. By activating cellular transport pumps to redistribute drugs away from organs and tissues where they have adverse effects, the company's compounds aim to minimize toxic side effects at non-targeted vulnerable organs and tissues while maintaining or enhancing a drug's desired effects. Per the company, Limerick's pipeline molecules are applicable to a broad range of therapeutic drug classes including immunosuppressants, opioids, immunomodulators, selective estrogens receptor modulators, and psychotropics. In the monotherapy setting, Limerick is developing novel compounds that target the treatment of metabolic diseases such as hypercholesteremia and hyperglycemia via a mechanism related to reverse cholesterol transport.